This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Third View - Digging into the Phase 2 Data on Spruce Bio's tildacerfont in treating Congenital Adrenal Hyperplasia (CAH)

Ticker(s): SPRB

Who's the expert?

Institution: Hofstra/Northwell Health

  • Chief, Division of Pediatric Endocrinology, Steven & Alexandra Cohen Children’s Medical Center of New York, Professor of Pediatrics at Hofstra/Northwell & Associate Professor, The Center for Pediatric Research, Feinstein Institute for Medical Research.
  • Currently manages 75 patients with CAH.
  • Chair of The Endocrine Society Task Force for Clinical Practice Guidelines for CAH, on the Medical Advisory Boards of The CARES Foundation and the National Adrenal Diseases Foundation, and involved in pharmaceutical trials to develop novel types of drug treatment for obesity, diabetes and congenital adrenal hyperplasia.

Interview Goal
This conversation will focus on the potential of tildacerfont in treating CAH. We'll focus on the two phase 2 studies of Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia. 

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.